TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06038409
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
Study: NCT05064306
Drug: 131I-omburtamab
Normalized name: 131I-omburtamab
DrugBank: Omburtamab I-131 (DB17124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mCi 131I-omburtamab
Study: NCT05324293
Drug: HMI-115
Normalized name: HMI-103
DrugBank: HMI-103 (DB17684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Every 2 weeks, subcutaneously injection
Study: NCT05403723
Drug: Durvalumab 50 MG/1 ML Intravenous Solution
Normalized name: Durvalumab 50 MG/1 ML Intravenous Solution
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
Study: NCT05403723
Drug: Etoposide Injection
Normalized name: etoposide Injection
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
Study: NCT05403723
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
Study: NCT05403723
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
Study: NCT05874700
Drug: Sivelestat sodium was given intravenously
Normalized name: Sivelestat
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
Study: NCT05928936
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
Study: NCT05399498
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 25mg capsule
Study: NCT05590377
Drug: Modakafusp Alfa
Normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modakafusp alfa intravenous infusion
Study: NCT05481658
Drug: Diphencyprone (DPCP)
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical immunomodulator
Study: NCT04161066
Drug: Psilocybin with facilitated counseling
Normalized name: Primatene with ephedrine Pill
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: open-label pilot study
Study: NCT05590377
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab SC injection
Study: NCT04991753
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab infusions will be administered intravenously.
Study: NCT00000794
Drug: Sulfadiazine
Normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000794
Drug: Atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000794
Drug: Pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05507294
Drug: Glumetinib
Normalized name: Glumetinib
DrugBank: Glumetinib (DB15630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration.
Study: NCT06497439
Drug: Silfamin
Normalized name: Sulfamine
DrugBank: Sulfanilamide (DB00259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of Silfamin 150 mg twice daily
Study: NCT05811442
Drug: 50561 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug
Study: NCT05811442
Drug: 50561 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: study drug
Study: NCT04765449
Drug: Cytotoxic T Lymphocytes
Normalized name: Allogeneic cytomegalovirus cytotoxic T lymphocytes
DrugBank: Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (DB17746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
Study: NCT06399263
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The psilocybin will include two dose administration sessions, first a 20mg administration, and second a 30mg administration.
Study: NCT05947344
Drug: STI-8591
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg, 60mg and 80mg. Expansion is planned in two dose groups of 40mg and 60mg.
Study: NCT05654623
Drug: ARV-471
Normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, once daily on a 28-day continuous dosing schedule
Study: NCT05654623
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
Study: NCT06515418
Drug: Oral Azelaprag (BGE-105)
Normalized name: Azelaprag
DrugBank: Azelaprag (DB19329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT06515418
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT05077215
Drug: Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
Study: NCT05077215
Drug: Lenvatinib Capsules
Normalized name: Lenvatinib Capsules
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
Study: NCT00265694
Drug: vinorelbine, gemcitabine and carboplatin
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05946655
Drug: Ofloxacin + Metronidazole
Normalized name: Ofloxacin
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
Study: NCT05133531
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered Intravenous (IV) per the protocol
Study: NCT05133531
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV and subcutaneous (SC) per the protocol
Study: NCT05133531
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC per the protocol
Study: NCT05133531
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV per the protocol
Study: NCT06001320
Drug: Letermovir 480 mg once daily
Normalized name: letermovir 480 MG
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.
Study: NCT06125834
Drug: Trastuzumab Emtansine (T-DM1)
Normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
Study: NCT06295159
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
Study: NCT06295159
Drug: Nivolumab + Relatlimab
Normalized name: nivolumab / relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
Study: NCT06295159
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor that may block CTLA-4 and help the immune system kill cancer cells. Ipilimumab binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair.
Study: NCT05490849
Drug: 68Ga-HX01
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis.
Study: NCT06009965
Drug: CsA+ATG+Herombopag
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
Study: NCT06009965
Drug: CsA+Herombopag
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
Study: NCT00000669
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05558696
Drug: Bomedemstat
Normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05519475
Drug: ALN-HSD
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection (SC)
Study: NCT06276465
Drug: Darolutamide 300 mg
Normalized name: darolutamide 300 MG
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation
Study: NCT05044637
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
Study: NCT05044637
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
Study: NCT05044637
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
Study: NCT04354636
Drug: Silver modified atraumatic restorative treatment
Normalized name: DRESSING,RESTORE SILVER
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver diamine fluoride that will be applied during atraumatic restorative treatment
Study: NCT05690984
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
Study: NCT05690984
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
Study: NCT05690984
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
Study: NCT05617677
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05932212
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
Study: NCT05932212
Drug: AK104+ Paclitaxel+Cisplatin or Carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.
Study: NCT05306080
Drug: Tadekinig alfa (IL-18BP)
Normalized name: Darbepoetin Alfa
DrugBank: Tadekinig alfa (DB14858)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS.
Study: NCT05042531
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
Study: NCT05042531
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dasatinib,20mg,po,qd,treatment cycles every 28 days
Study: NCT05909618
Drug: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
Normalized name: Crizanlizumab-tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
DrugBank: Crizanlizumab (DB15271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/kg solution for injection
Study: NCT05909618
Drug: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
Normalized name: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/mL solution for injection
Study: NCT05897541
Drug: S-217622
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a tablet.
Study: NCT05254626
Drug: Dapagliflozin 10Mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
Study: NCT05254626
Drug: Pioglitazone 30 mg
Normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
Study: NCT05972720
Drug: Fludarabine (Conditional therapy)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepletion chemotherapy
Study: NCT05972720
Drug: firi-cel (Experimental drug)
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational agent